[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,857,482
  • Shares Outstanding, K 43,828
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 1,335 M
  • EBIT $ 1,493 M
  • EBITDA $ 1,578 M
  • 60-Month Beta 0.75
  • Price/Sales 7.89
  • Price/Cash Flow 17.37
  • Price/Book 3.48

Options Overview Details

View History
  • Implied Volatility 40.25% (+2.10%)
  • Historical Volatility 40.65%
  • IV Percentile 61%
  • IV Rank 21.12%
  • IV High 92.62% on 08/25/25
  • IV Low 26.23% on 06/18/25
  • Expected Move (DTE 19) 35.87 (6.32%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 317
  • Volume Avg (30-Day) 3,234
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 33,021
  • Open Int (30-Day) 45,410
  • Expected Range 531.29 to 603.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $6.73
  • Number of Estimates 7
  • High Estimate $7.41
  • Low Estimate $6.36
  • Prior Year $6.63
  • Growth Rate Est. (year over year) +1.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
520.97 +8.87%
on 03/27/26
607.89 -6.70%
on 03/30/26
+35.34 (+6.65%)
since 03/24/26
3-Month
462.02 +22.76%
on 01/30/26
607.89 -6.70%
on 03/30/26
+98.22 (+20.95%)
since 01/23/26
52-Week
272.12 +108.42%
on 07/31/25
607.89 -6.70%
on 03/30/26
+270.74 (+91.34%)
since 04/24/25

Most Recent Stories

More News
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026...

UTHR : 567.16 (-0.99%)
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlier detection and management of pulmonary hypertension ( PH ...

UTHR : 567.16 (-0.99%)
3 Reasons Investors Love United Therapeutics (UTHR)

3 Reasons Investors Love United Therapeutics (UTHR)

UTHR : 567.16 (-0.99%)
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Regenerative Medicine...

UTHR : 567.16 (-0.99%)
3 Market-Beating Stocks for Long-Term Investors

3 Market-Beating Stocks for Long-Term Investors

CCB : 82.27 (-1.93%)
CVX : 185.21 (-1.27%)
UTHR : 567.16 (-0.99%)
Stocks Pressured by Economic Fallout from Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.78%. June E-mini...

AMAT : 417.04 (+3.25%)
SNDK : 989.90 (+6.16%)
INTU : 395.95 (+3.30%)
$IUXX : 27,303.67 (+1.95%)
LITE : 881.64 (+4.10%)
UTHR : 567.16 (-0.99%)
ASML : 1,457.70 (+2.81%)
ZNM26 : 111-040 (-0.08%)
GLW : 175.89 (+3.77%)
ESM26 : 7,204.00 (+0.13%)
STX : 586.25 (-0.23%)
WDC : 404.00 (+0.22%)
Why United Therapeutics (UTHR) Stock Is Up Today

Why United Therapeutics (UTHR) Stock Is Up Today

UTHR : 567.16 (-0.99%)
Markets Turn Negative as Crude Oil Prices Surge

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.18%. Stock indexes turned lower...

AMAT : 417.04 (+3.25%)
AVGO : 422.76 (+0.67%)
INTU : 395.95 (+3.30%)
DDOG : 129.48 (+1.27%)
EXPE : 251.44 (+0.43%)
$IUXX : 27,303.67 (+1.95%)
UTHR : 567.16 (-0.99%)
ASML : 1,457.70 (+2.81%)
ZNM26 : 111-040 (-0.08%)
CLK26 : 92.13s (+2.81%)
STX : 586.25 (-0.23%)
WDC : 404.00 (+0.22%)
Stocks Rebound as T-note Yields Tumble

The S&P 500 Index ($SPX ) (SPY ) today is up +0.42%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. June E-mini S&P futures (ESM26...

MSTR : 171.02 (-0.84%)
INTU : 395.95 (+3.30%)
DDOG : 129.48 (+1.27%)
GLXY : 26.00 (-1.05%)
EXPE : 251.44 (+0.43%)
$IUXX : 27,303.67 (+1.95%)
COIN : 199.77 (+0.93%)
UTHR : 567.16 (-0.99%)
ZNM26 : 111-040 (-0.08%)
ESM26 : 7,204.00 (+0.13%)
$DOWI : 49,230.71 (-0.16%)
^BTCUSD : 79,217.85 (+1.89%)
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

Nebulized Tyvaso ® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical...

UTHR : 567.16 (-0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 585.73
2nd Resistance Point 579.21
1st Resistance Point 573.19
Last Price 567.16
1st Support Level 560.65
2nd Support Level 554.13
3rd Support Level 548.11

See More

52-Week High 607.89
Last Price 567.16
Fibonacci 61.8% 479.63
Fibonacci 50% 440.01
Fibonacci 38.2% 400.38
52-Week Low 272.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.